ILiAD Biotechnologies
ILiAD Biotechnologies (ILiAD) is a clinical-stage biotechnology company focused on the prevention and treatment of disease caused by Bordetella Pertussis. ILiAD's lead candidate is BPZE1, a live-attenuated pertussis vaccine that has successfully completed a Phase 1 human clinical trial. ILiAD Biotechnologies is a registered Delaware company founded in 2012.
Domain
iliadbio.com
Country
United StatesIndustry
BiotechnologyEmployees
11-50
Last Funding
$115.0M
Founded
2011
Tech Stack (8 technologies)
Frequently Asked Questions
What technologies does ILiAD Biotechnologies use?+
ILiAD Biotechnologies uses 8 technologies including Google Analytics, Google Tag Manager, Slider Revolution.
What industry is ILiAD Biotechnologies in?+
ILiAD Biotechnologies operates in the Biotechnology industry.
Where is ILiAD Biotechnologies based?+
ILiAD Biotechnologies is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026